![]() ![]() In addition to traditional pharmacological treatment, which is the first choice, there are other emerging anti-anginal drugs, whose prescription rate is low, e.g., 1.4% for ranolazine and 4.1% for ivabradine. This presentation occurs in between 5% and 10% of cases and it is responsible for an annual mortality of between 2% and 4%. When, in spite of optimal medical treatment, angina is persistent, it is defined as refractory angina. The prognosis of angina pectoris depends on the patient's clinical profile and its approach, resulting in an annual mortality of up to more than 3%. ![]() A recent European registry in 10 countries including 2,420 patients with chronic coronary artery disease showed that the age was more advanced and the patients presented more comorbidities when compared to the Euro Heart Survey data, published in 2005, which included 3,779 patients. ![]() Data from the National Center for Health Statistics and National Heart, Lung, and Blood Institute demonstrate the increase in angina pectoris with age, reaching a frequency of 11.8% and 10.9% for women and men, respectively, who are at least 80 years old. The prevalence of angina pectoris is 3.4% in the population ≥20 years, and the age-adjusted prevalence is higher in women, especially Hispanic women, considering the population between 40 and 75 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |